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Abstract
Introduction: We previously reported that in artificially-fed critically ill patients, adipose tissue reveals an increase
in small adipocytes and accumulation of M2-macrophages. We hypothesized that nutrient-independent factors of
critical illness explain these findings, and that the M2-macrophage accumulation may not be limited to adipose
tissue.
Methods: In a long-term cecal ligation and puncture (CLP) mouse model of sepsis, we compared the effect of
parenteral nutrition (CLP-fed, n = 13) with nutrient restriction (CLP-restricted, n = 11) on body composition,
adipocyte size and macrophage accumulation in adipose tissue, liver and lungs. Fed healthy mice (n = 11) were
studied as controls. In a human study, in vivo adipose tissue biopsies were studied from ICU patients (n = 40)
enrolled in a randomized control trial which compared early initiation of parenteral nutrition (PN) versus tolerating
nutrient restriction during the first week of ICU stay. Adipose tissue morphology was compared with healthy
human controls (n = 13).
Results: Irrespective of nutritional intake, critically ill mice lost weight, fat and fat-free mass. Adipocyte number,
proliferation marker Proliferating Cell Nuclear Antigen (PCNA) and adipogenic markers PPARg and CCAAT/enhancer
binding protein-b (C/EBPb) increased with illness, irrespective of nutritional intake. M2-macrophage accumulation
was observed in adipose tissue, liver and lungs of critically ill mice. Macrophage M2-markers correlated with CCL2
expression. In adipose tissue biopsies of critically ill patients, increased adipogenic markers and M2 macrophage
accumulation were present irrespective of nutritional intake.
Conclusions: Adipogenesis and accumulation of tissue M2-macrophages are hallmarks of prolonged critical illness,
irrespective of nutritional management. During critical illness, M2-macrophages accumulate not only in adipose
tissue, but also in the liver and lungs.
Introduction
Several observational studies have shown lower mortal-
ity in overweight and obese versus lean critically ill
patients, an association known as the ‘obesity paradox’
[1-4]. We previously documented increased formation of
small adipocytes during critical illness with increased
glucose and lipid storage properties [5,6]. These changes
might be beneficial during critical illness as newly-
formed, small adipocytes with augmented insulin
sensitivity and lipid-storage capacity might prevent
excess circulating lipids and glucose [7]. In addition, we
demonstrated a remarkable macrophage accumulation
in adipose tissue of critically ill patients with a predomi-
nant M2-phenotype [6]. Increased insulin sensitivity and
b-oxidation of free fatty acids (FFA), but also phagocyto-
sis of infectious microorganisms, production of anti-
inflammatory and tissue-healing factors are potential
beneficial features of M2-macrophages during critical
illness (CI) [8].
These previous observations were based on biopsies
from prolonged severely ill patients who had received
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parenteral nutrition (PN) throughout the ICU stay. The
observed changes in adipose tissue (AT) might thus be
related to the administration of PN or to nutrition-inde-
pendent factors. In health, excessive caloric intake pro-
motes hypertrophy and hyperplasia of adipocytes, and
accumulation of M1-macrophages [4,9]. Macrophage
accumulation could also be evoked by catecholamines
and hypoxia, factors accepted to play a role in the
pathophysiology of sepsis [10,11]. It is thus plausible
that other tissues involved in innate immunity could
also display macrophage accumulation during CI.
We hypothesized that nutrition-independent factors
evoke the morphological changes in AT during CI. We,
therefore, studied the impact of PN administration, as
compared with nutrient restriction, on body composi-
tion, adipogenesis and macrophage accumulation in AT,
liver and lungs in an antibiotic-treated fluid-resuscitated
mouse model of sepsis. In addition, we studied adipo-
genesis and macrophage accumulation in subcutaneous
AT biopsies harvested in vivo after one week of critical
illness from human patients enrolled in a randomized,
controlled trial (RCT) in which early initiation of PN
was compared with tolerating nutrient restriction in the
first seven days of ICU stay [12].
Materials and methods
Set-up of the experimental animal model
The protocol for this study was approved by the Institu-
tional Ethical Committee for Animal Experimentation
(project number P051/2010). Male, 24-week old, C57BL/
6J mice (Janvier SAS, Chassal, France) were anesthetized
with an intraperitoneal (i.p.) injection of ketamine
(3 mg, Univet, Heusden-Zolder, Belgium) and xylazine
(0.4 mg, VMD, Brussels, Belgium) and submitted to
dual-energy-X-ray-absorptiometry (DEXA) to identify
body composition (Lunar PIXImus™, GE Medical-Lunar,
Madison, WI, USA) (Figure 1). After a 48-hour recovery,
animals were again anaesthetized by i.p. injection of keta-
mine and xylazine. Animals were placed on a heating pad
maintained at 25°C. Spontaneously breathing mice were
continuously inhaling 1 to 2% isoflurane-vet (Schering-
Plough, Hull, UK) with oxygen (2L/min) through a facial
mask. The left central jugular vein was dissected under
microscopy and a sterilized Renathane catheter (model
MRE025; Braintree Scientific, Braintree, MA, USA) was
inserted. The catheter was tunneled to the back, attached
to a single-channel-fluid-swivel (model 375/25; Instech
Laboratories, Plymouth Meeting, PA, USA) allowing free
movement and continuous perfusion according to
the resuscitation scheme (Figure 1). Sepsis was produced
by a 50% ligation of the cecum (at half the distance
between the distal pole and the base of the cecum) with a
3.0 silk suture (Mersilk, Ethicon, Johnson & Johnson, St.-
Stevens-Woluwe, Belgium), and a single puncture
through-and-through with a 20-gauge needle. The cecum
was gently squeezed to extrude feces and returned to its
original position [13-15]. Surgical wounds were closed
with 7.0 silk sutures (Mersilk, Ethicon, Johnson & John-
son, St.-Stevens-Woluwe, Belgium). Post-operative
analgesia was provided by local infiltration of the surgical
wounds with ropivacaine (1%, AstraZeneca, Brussels,
Belgium) and subcutaneous (sc) administration of bupre-
norphine (9 μg, Schering-Plough, UK). Mice received the
broad-spectrum antibiotic Imipenem (0.25 mg sc, Mero-
penem, AstraZeneca, Brixham, UK) and continuous
intravenous fluid-resuscitation (NaCl0.45%/glucose2.5% +
6% hydroxyethyl starch (Voluven, Fresenius Klabi,
Schelle, Belgium)) in a 4:1 proportion at 0.5 ml/H for the
first 18 hours [16]. Afterwards, animals were randomly
allocated to the “restricted” or “fed” protocol. Animals in
the ‘CLP-restricted’ protocol (n = 13) received progres-
sive increments of NaCl0.45%/glucose50% (0.4 to 1.3 Kcal/
day). Animals in the ‘CLP-fed’ protocol (n = 14) received
increments of total parenteral nutrition (TPN) (consist-
ing of 29% kcal from lipids, 14% kcal from amino acids,
and 57% kcal from glucose) from 2.9 to 8.6 Kcal/day
(Clinomel N7, Baxter, Braine-l’Alleud, Belgium). Healthy
controls (n = 11) received 5 g of standard chow daily (13
kcal/24 h). A nutrient-restricted healthy group (pair-fed
for the CLP-restricted group) was unfeasible as the
restricted nutrient intake was lethal for healthy mice.
Every 12 hours septic mice received sc 0.25 mg Imipe-
nem and 9 to 12 μg buprenorphine. Buprenorphine was
chosen because it shares clinical attributes of standard
opioid analgesics but evokes less respiratory depression
and minor immune suppression in mice models [17].
Post-operative pain was regularly assessed by the Mice
Grimace Scale [18]. All mice were kept normoglycemic
(80 to 120 mg/dl) with iv infusion of insulin (Actrapid
Penfill, Novo Nordisk, Bagsvaerd, Denmark) using an in-
house developed protocol. To avoid hypothermia, the
cage temperature was kept at 27 ± 1°C with heating
lamps. Animals that lost their catheter were excluded
from the study. After five days, surviving animals were
submitted to a second DEXA-scan, and sacrificed by
decapitation. Due to technical problems, not all mice
were scanned twice. Blood was collected from the trunk,
and organs were removed. AT was removed from the
inguinal, epididymal and peri-renal sites. All tissue sam-
ples were snap-frozen in liquid nitrogen and stored at
-80°C until analysis. Due to the small size of AT biopsies,
not all biopsies could be analyzed for both immunocyto-
chemistry and RNA analysis.
Human study
Patients were enrolled in a large RCT (n = 4,640) to
compare early versus late initiation of parenteral nutri-
tion to supplement failing enteral feeding during the
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first week of CI. Details of the study were previously
published [19]. The protocol and consent forms were
approved by the Institutional Ethical Review Board
(ML4190). During the randomized control trial, subcuta-
neous biopsies were collected from 188 patients. To
avoid bias of prior-to-illness body mass index (BMI)-
related changes in the AT, only patients with a normal
BMI (between 18 to 25 kg/m2) were selected for this
study (n = 72). From these 72 patients, 20 early PN and
20 late PN patients, matched for admission characteris-
tics and illness severity (Table 1), were compared with
13 healthy demographically-matched volunteers. On Day
8 ± 1 of the ICU stay, a subcutaneous in vivo AT biopsy
was collected in the quadriceps region with a 5-mm-
Bergström muscle-biopsy cannula according to the pro-
tocol described earlier [6]. The biopsy specimens were
snap frozen in liquid nitrogen and stored at -80°C.
Triglyceride content in liver and skeletal muscle
Triglyceride content of tissue was determined with a
colorimetric commercial assay (triglyceride quantifica-
tion kit, Abcam, Cambridge, UK).
Figure 1 Experimental set-up of the animal work. (A) Timeline and mortality of the model. (B) Caloric intake: all mice received total
parenteral nutrition (TPN) or saline + glucose through an indwelling jugular catheter. The administered fluid/TPN regimen was stepwise
increased from 0.1 ml/H to the maximum sustained dose of 0.3 ml/H.
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Immunohistochemistry
Paraformaldehyde-fixed paraffin sections were stained
with F4/80Ab (general anti-macrophage antibody (Ab)
for mice (Abcam)), CD163Ab (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and Peroxisome Proliferator-Acti-
vated Receptor Gamma (PPARg)-Ab (Abcam). For
human samples, the general macrophage marker CD68
was used (Dako, Glostrup, Denmark). Macrophage accu-
mulation in AT sections was evaluated in a blinded fash-
ion by two observers on a Leica DM3000 Microscope
(Wetzlar, Germany). Macrophage staining in liver and
lungs, PPARg staining in AT and adipocyte size were
quantified on digital microscopical images with in-house
designed algorithms developed in Matlab 7.4.0 and Image
Processing Toolbox (Matworks, Natick, MA, USA) as
described earlier [20]. The estimated proportion of adipo-
cytes was calculated by dividing total end weight of body
fat (second DEXA quantification) by mean adipocyte
size. This calculation was then plotted proportionally to
the mean estimated number of adipocytes of the healthy
mice [21].
Gene expression
Messenger RNA was isolated and cDNA quantified in real
time as previously described [22]. Data are expressed nor-
malized to GAPDH or HPRT as fold-change of the mean
of the control group. For the quantification of Proliferating
Cell Nuclear Antigen (PCNA), CCAAT/enhancer binding
protein-b (C/EBPb), hormone sensitive lipase (HSL),
tumor necrosis factor-a (TNFa), inducible nitric oxide
synthase (iNOS), Arginase-1, interleukin 10 (IL-10), che-
mokine (C-C motif) ligand 2 (CCL2), and CD-163 messen-
ger RNA, commercial gene expression assays (TaqMan,
Life Technologies, Gent, Belgium) were used.
Statistics
The following predefined statistical plan was used: (1) to
assess the impact of illness, the fed healthy controls were
compared with the CLP-fed; (2) to assess the impact of
feeding during illness, the CLP-fed were compared with
the CLP-restricted. Unpaired t-test was used for normally
distributed data; the non-parametric Mann-Whitney u
test for non-normally distributed data. Exponential gene
expression data were log transformed. For comparison of
proportions, the X-square test was used. The significance
of correlations was assessed by calculation of the Pearson
(r) correlation coefficient. Statistical significance was con-
sidered when P-values ≤ 0.05.
Results
Mouse study - impact of PN during CI on body
composition, adipogenesis and lipolysis
The beginning bodyweight of the animals was 29.3 ± 0.4 g
(mean ± SE), of which 4.2 ± 0.1 g were fat. Changes in
body composition were quantified in eight animals per
group. CLP-fed animals lost weight, total body fat mass
and total body fat-free mass as compared with healthy ani-
mals (Figure 2A-C). The loss of fat mass in CLP-fed mice
Table 1 Baseline and outcome variables of studied critically ill patients and healthy volunteers
Early PN patients
N = 20
Late PN patients
N = 20
P-value Early vs.
Late
Healthy Controls
N = 13
P-value Ill vs.
Healthy
Demographic data
Male sex - no. (%) 15 (75) 14 (70) 0.7 8 (62) 0.6
Age - yr (mean ± SE) 60 ± 2 63 ± 3 0.1 60 ± 3 0.4
BMI - Kg/m2 (mean ± SE) 23.1 ± 0.9 23.2 ± 1.2 0.7 23.9 ± 1.3 0.1
Comorbidity parameters
Malignancy no. (%) 6 (30) 5 (25) 0.7
Diabetes no. (%) 3 (15) 1 (5) 0.3
NRS score - median [IQR] 4 [3 to 7] 4 [3 to 6] 0.4
APACHE II SCORE - median
[IQR]
30 [21 to 47] 33 [23 to 42] 0.6
Reason for admission - no. (%) 0.7
Complicated Surgery/
Trauma
11 10
Medical 5 7
Transplant 3 2
Cardiac surgery 1 1
Outcome variables
New infection - no (%) 14 (70) 15 (75) 0.7
Duration of ICU stay - median
[IQR]
15 [10 to 33] 18 [10 to 40] 0.7
ICU non-survivors - no (%) 3 (15) 4 (20) 0.7
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corresponded to a 26% reduction in total body fat mass
(from mean 4.1 ± 0.1 g to 3.4 ± 0.2g). CLP-fed and CLP-
restricted animals showed a comparable reduction in lost
weight, fat mass and fat-free mass.
Part of the fat was lost from ectopic sites, evidenced
by lowered triglyceride content in liver and skeletal
muscle in CLP-fed compared to healthy mice. Reduction
of triglyceride content from liver and skeletal muscle
was further accentuated in CLP-restricted compared to
CLP-fed animals (Figure 2D). Total body fat mass corre-
lated with triglyceride content in liver and muscle (R =
0.625, P = 0.01).
Adipocytes of CLP-fed mice were smaller than in healthy
controls in subcutaneous (46% smaller), epididymal (62%
smaller) and renal AT (51% smaller) (Figure 3A). CLP-
restricted mice showed a comparable reduction in adipo-
cyte size as CLP-fed mice. Because smaller adipocytes
could theoretically be explained by more newly formed
small adipocytes (adipogenesis), or by adipocytes releasing
stored triglycerides (lipolysis), we quantified markers for
both processes. To assess lipolysis, gene expression of HSL,
the rate-limiting enzyme in the release of stored triglycer-
ides, was quantified. HSL gene expression was lower in
CLP-fed than in healthy animals in subcutaneous AT (med-
ian (IQR) 1.3 (0.8 to 1.5) to 0.4 (0.4 to 0.5) Arbitrary Units
(AU), P = 0.05) and renal AT (1.0 (0.9 to 1.2) to 0.6 (0.6 to
0.7) AU, P = 0.005). In the epididymal AT, HSL gene
expression tended (P = 0.1) to be lower in CLP-fed than in
healthy mice. There was a significant further reduction of
HSL gene expression in visceral (P = 0.004), but not in sub-
cutaneous AT (P = 0.7) of CLP-restricted compared to
CLP-fed mice.
To assess adipogenesis, the number of adipocytes was
estimated by dividing total body fat mass by adipocyte
size: CLP-fed mice displayed 50% higher number of adipo-
cytes compared to healthy mice (Figure 3B). CLP-fed and
CLP-restricted mice showed a comparable increased num-
ber of adipocytes. Gene expression of the proliferation
Figure 2 Changes in mouse body composition over five days of sepsis. The box plots represent the changes from baseline to Day 5
(referred to as “Δ”) of total body weight (A), total body fat mass (B), total body fat-free mass (C) and triglyceride content in non-adipose tissues,
liver and muscle (D). Data boxes present median and IQR; whiskers represent the 10th and the 90th percentiles. White boxes present healthy
controls (n = 8), light gray boxes are critically ill mice allocated to the total parenteral nutrition (TPN) protocol (cecal ligation and puncture (CLP)-
fed) (n = 8), and dark gray boxes are critically ill mice allocated to the nutrient restriction (CLP-restricted) protocol’ (n = 8).
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Figure 3 Adipogenic markers in subcutaneous and visceral adipose tissue of septic mice. The box plots represent median adipocyte size
(A), estimated proportion of adipocytes and representative microscopic adipose tissue images of a healthy and a cecal ligation and puncture
(CLP)-fed mouse (B), Proliferating Cell Nuclear Antigen (PCNA) gene expression (C), percentage stained area for peroxisome proliferator-activated
receptor g (PPARg) (D), mRNA gene expression of CCAAT/enhancer binding protein-b (C/EBPb) (E). AT is adipose tissue, A.U. is arbitrary units.
Data boxes present median and IQR; whiskers represent the 10th and the 90th percentiles. For immunocytochemistry analyses in A, B and D,
White boxes present healthy controls (n = 10), light gray boxes are critically ill mice allocated to the total parenteral nutrition (TPN) protocol
(CLP-fed) (n = 6), and dark gray boxes are critically ill mice allocated to the nutrient restriction protocol (CLP-restricted) (n = 8). For gene
expression analyses, the number of animals are healthy controls (n = 8), CLP-fed (n = 7), CLP-restricted (n = 6).
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marker PCNA was up-regulated in CLP-fed mice com-
pared to healthy controls in subcutaneous and renal AT
(not in epidydimal AT). CLP-fed and CLP-restricted mice
showed a comparable PCNA gene expression (Figure 3C).
Immunostaining of the adipogenic transcription factor
PPARg was significantly higher in CLP-fed compared
to healthy mice in all AT depots. CLP-fed and CLP-
restricted mice showed comparable PPARg immunostain-
ing (Figure 3D). C/EBPb expression was higher in CLP-fed
than in healthy animals in all AT depots. In subcutaneous
AT, CLP-restricted mice showed a further increase in C/
EBPb gene expression when compared to CLP-fed mice
(Figure 3E). In visceral AT, CLP-fed and CLP-restricted
mice showed comparable increase in C/EBPb gene
expression.
Mouse study: impact of PN during CI on tissue
macrophages
Immunostaining revealed that macrophages accumulated
in all AT depots of CLP-fed animals compared with
healthy animals. There was comparable accumulation of
macrophages in CLP-fed and CLP-restricted animals
(Table 2). Macrophages can polarize to either an M1- or
an M2-phenotype, each expressing distinct markers. We
quantified gene expression of TNFa and iNOS as M1-
markers; and arginase-1, IL10 and CD163 as M2-markers.
In subcutaneous AT of CLP-fed mice, gene expression of
TNFa and iNOS was similar to healthy mice (Figure 4A,
B). In contrast, the M2-markers arginase-1, IL-10 and
CD163 were markedly up-regulated in subcutaneous AT
of CLP-fed mice compared to healthy mice. In visceral
AT, TNFa (renal and epididymal) and iNOS (renal) gene
expressions were increased up to two-fold in CLP-fed
compared to healthy mice (Figure 4A, B). In contrast, gene
expression of the M2-marker arginase-1 increased more
than 10-fold in CLP-fed compared to healthy mice.
Expression of M1 and M2 markers was comparable in
CLP-fed and CLP-restricted mice in all AT depots
(Figure 4). Only in subcutaneous and epididymal AT,
iNOS was reduced and in renal AT, arginase expression
was further increased in CLP-restricted compared to
CLP-fed mice. Subcutaneous and visceral AT sections
were immunostained for CD163. Positive M2 macro-
phage staining was present in all AT depots of CLP-fed
and CLP-restricted mice.
Immuno-staining revealed that macrophages also
accumulated in the liver and lungs of CLP-fed compared
with healthy mice (Figure 5). This increased staining
corresponded in the liver and lungs with an increased
expression of both M1-marker TNFa and M2-markers
arginase-1 and CD163. In the liver, macrophage
immuno-staining correlated significantly with CD163
gene expression (R = 0.541, P = 0.002) and with TNFa
gene expression (R = 0.405, P = 0.003). There was equal
accumulation of macrophages in the liver and lungs of
CLP-fed and CLP-restricted mice. Also, expression of
M1-marker TNFa and M2-marker arginase-1 was com-
parable in CLP-fed and CLP-restricted mice. In contrast,
expression of M2-marker CD163 was further increased
in CLP-restricted when compared to CLP-fed mice
(Figure 5).
As a possible trigger for the macrophage accumula-
tion, we quantified gene expression of the chemo-attrac-
tant factor CCL2. The gene expression of CCL2 was
higher in all AT depots, lungs and liver of CLP-fed
when compared to healthy mice (Figures 4F and 5). The
gene expression of CCL2 in CLP-fed and CLP-restricted
mice was comparable in all AT depots, lungs and liver.
CCL2 expression correlated positively with arginase
expression (R = 0.566, P = 0.007 in inguinal AT, R =
0.912, P < 0.0001 in epidydimal AT, R = 0.598, P =
0.009 in renal AT). CCL2 gene expression correlated
Table 2 Macrophage accumulation in adipose tissue of septic mice
Macrophage
Accumulation
Score 0 Score 1 Score 2 P-values
Subcutaneous AT
Healthy (n = 8) 100% - -
CLP-fed (n = 6) - 83% 17% Ill vs Healthy: P = 0.0009
CLP-restricted (n = 6) - 33% 67% Fed vs Restricted: P = 0.6
Epidydimal AT
Healthy (n = 6) 100% - -
CLP-fed (n = 6) - 33% 67% Ill vs Healthy: P = 0.01
CLP-restricted (n = 7) - 28% 72% Fed vs Restricted: P = 0.8
Renal AT
Healthy (n = 11) 64% 27% 9%
CLP-fed (n = 11) - 55% 45% Ill vs Healthy: P = 0.005
CLP-restricted (n = 5) - 40% 60% Fed vs Restricted: P = 0.6
Every sample received a score 0 (no positive cells visible), score 1 (intermediate number of positive cells), or 2 (high number of positive cells). AT, adipose tissue
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Figure 4 M1/M2 phenotyping of the macrophages in subcutaneous and visceral adipose tissue of septic mice. Gene expression of the
M1-type macrophage marker tumor necrosis factor alpha (TNFa) (A), and inducible nitrous oxide synthase (iNOS) (B), Gene expression of the
M2-type macrophage markers Arginase 1 (C), interleukin (IL)10 (D), and CD163 (E). Gene expression of the chemoattractant factor chemokine
ligand 2 (CCL2) (F). AT is adipose tissue, A.U. is arbitrary units. Data boxes present median and IQR; whiskers represent the 10th and the 90th
percentiles. White boxes present healthy controls (n = 8), light gray boxes are critically ill mice allocated to the total parenteral nutrition (TPN)
protocol (cecal ligation and puncture (CLP)-fed) (n = 7), and dark gray boxes are critically ill mice allocated to the nutrient restriction protocol
(CLP-restricted) (n = 6).
Marques et al. Critical Care 2013, 17:R193
http://ccforum.com/content/17/5/R193
Page 8 of 14
Figure 5 Macrophage accumulation in the liver and lungs of septic mice. The upper panel displays liver parameters, the bottom panel
displays lung parameters. Representative microscopic image of tissue macrophage staining (A, G). Computerized quantification of macrophage
immunostaining (B, H). Gene expression of the M1-type macrophage marker tumor necrosis factor alpha (TNFa) (C, I), and M2-markers Arginase-
1 (D, J) and CD163 (E, K). Gene expression of the chemo-attractant factor chemokine ligand 2 (CCL2) (F, L). AU is arbitrary units. Data boxes
present median and IQR; whiskers represent the 10th and the 90th percentiles. White boxes present healthy controls (n = 13), light gray boxes
are critically ill mice allocated to the total parenteral nutrition (TPN) protocol (cecal ligation and puncture (CLP)-fed) (n = 11), and dark gray
boxes are critically ill mice allocated to the restriction protocol (CLP-restricted) (n = 11).
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positively with CD163 gene expression in the liver (R =
0.424, P = 0.01) and lungs (R = 0.730, P < 0.0001).
Human study: impact of PN during CI on adipose tissue
morphology and gene expression
To assess the clinical relevance of our animal study obser-
vations, we additionally studied a matched set of 40
human AT biopsies collected in vivo during the EPaNIC
trial [12]. Small needle biopsies were collected at Day 8,
and compared with 13 biopsies from healthy volunteers.
Total caloric intake was significantly higher in early-PN
patients (n = 20) compared to late-PN (n = 20) patients
during the first seven days in the ICU (Figure 6A).
Adipocyte size decreased in early PN ‘fed’ critically-ill
patients compared to healthy controls (Figure 6B).
Medium adipocyte size was equally reduced in early PN
‘fed’ patients and late PN ‘restricted’ patients. Immuno-
staining revealed accumulation of macrophages in all biop-
sies of critically-ill patients (Figure 6C). Gene expression of
TNFa was unaffected by illness, while arginase-1 gene
expression was higher in early PN ‘fed’ critically-ill patients
than in controls (Figure 6D, E). Gene expression of TNFa
was equally up-regulated in early PN ‘fed’ and late PN
‘restricted’ patients.
It is known from the literature that glucocorticoids
can both stimulate adipogenesis [23] and promote M2
polarization [24]. Nineteen of the 40 patients received
corticosteroids during the study period. However, argi-
nase expression (P = 0.25), TNFa expression (P = 0.47)
and adipocyte size (P = 0.6) were not different between
patients receiving or not receiving steroids. In contrast,
patients receiving steroids during the study period, had
a higher percentage of CD68 staining then patients not
receiving steroids (P = 0.03).
Discussion
Sepsis-induced critical illness in mice evoked nutrition-
resistant loss of body weight, fat-free mass and fat mass,
the latter partially explained by ectopic triglyceride loss.
Concomitantly, critical illness increased adipogenesis
resulting in an increased number of smaller adipocytes,
irrespective of nutrition. Macrophages of a predominant
M2-phenotype, accumulated in subcutaneous and visc-
eral AT as well as in the liver and lungs of both fed and
fasted septic mice. In the liver and lungs, fasting
appeared to further enhance M2 over M1 polarization. In
all tested tissues of the septic mouse model, increased
expression of the chemotatic factor CCL2 correlated posi-
tively with macrophage accumulation. In the human study,
we could confirm that increased adipogenesis and M2-
macrophage accumulation in the adipose tissue was present
in critically-ill patients, independent from parenteral nutri-
tion administration.
Critical illness uniformly induces hypercatabolism,
characterized by profound loss of lean tissue [25]. In
humans, aggressive artificial nutrition was shown unable
to prevent lean tissue wasting, whereas fat mass was
preserved or even increased [26-28]. In our septic
mouse model, we observed loss of both fat and fat-free
mass after five days of critical illness in both CLP-fed
and CLP-restricted mice. The 26% reduction in total
body fat mass in mice may seem to contradict the avail-
able human data [26,28]. This discrepancy might be due
to the length of our experimental animal set-up, as five
days can be considered quite an extended time for mice.
On the other hand, the methodology used in our experi-
ment allowed the quantification of the total amount of
fat in the body, including ectopic lipid depositions.
Indeed, we demonstrated a reduction of triglyceride
content in non-adipose tissues, such as liver and skeletal
muscle, a reduction which was even more pronounced
with nutrient restriction. Our observation of triglyceride
reduction in liver does not contradict the known occur-
rence of fatty liver in critically ill patients, because our
mouse model was well controlled for hyperglycemia,
which is a major trigger for hepatic steatosis during cri-
tical illness [29,30].
Although some of the body fat mass was probably lost in
the AT depots, the 26% reduction in total body fat mass
contrasted sharply with the more than 40% reduction in
median adipocyte size, indicating other factors involved in
the decreased adipocyte size. Indeed, the observed reduc-
tion in adipocyte size could not be explained by lipolysis,
as HSL expression was strongly reduced by illness and
further reduced by fasting during illness. Instead, our data
indicate that the increased number of small adipocytes
resulted from increased adipogenesis. Indeed, the prolif-
eration marker PCNA and nuclear transcription factors
C/EBPb and PPARg were up-regulated, factors that are
essential and sufficient to induce white adipocyte differen-
tiation from stem cells [31]. The increase of the adipogenic
markers was unaffected by nutrition, suggesting an illness-
related trigger. A possible role of increased adipogenesis
during critical illness would be to better deal with toxic
metabolites, such as circulating triglycerides and glucose
[32,33], preventing their accumulation in the liver and
muscle. Newly-formed small adipocytes indeed have an
increased capacity of storing triglycerides and glucose
from the circulation [6,7,34]. Unexpectedly, fasting during
CI further reduced lipolysis in visceral AT. This may sug-
gest that during critical illness, fasting either does not sig-
nal the adipose tissue to release stored triglycerides or that
increased adipogenesis evoked by illness overwhelms any
lipolytic response.
The second important alteration we observed in AT dur-
ing CI, again unaffected by nutrition, was the accumulation
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Figure 6 Adipogenesis and macrophage accumulation in human in vivo subcutaneous adipose tissue biopsies. Total caloric intake
during first seven days in ICU (A), Median adipocyte size (B), Computerized quantification of macrophage immunostaining (C), Gene expression
of the M1-type macrophage marker tumor necrosis factor alpha (TNFa) (D), Gene expression of the M2-type macrophage marker Arginase1
(E). AU is arbitrary units. Data boxes present median and IQR; whiskers represent the 10th and the 90th percentiles. White boxes present healthy
volunteers (n = 13), light gray boxes are critically ill patients allocated to the early parenteral nutrition (PN) protocol (n = 20), and dark gray
boxes are patients allocated to the late PN protocol (n = 20).
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of macrophages. Similarly to the AT, the lungs and liver of
critically ill mice showed a clear accumulation of macro-
phages, unaffected by nutrition. In all studied tissues, the
markers for macrophage accumulation correlated strongly
with CCL2, suggesting an orchestrated response to illness
in innate immune-related organs. Cellular hypoxia and
catecholamines, known to stimulate production and secre-
tion of chemoattractant factors, may play a role in this pro-
cess [10,35-37]. Additionally, recruited macrophages and
adipocytes could further evoke catecholamine release indu-
cing a vicious circle [38,39].
Depending on the trigger, tissue macrophages can
polarize to the pro-inflammatory M1-state or to the
anti-inflammatory M2-state [8]. The activation of M1
macrophages is a classical feature of cellular immune
response to infection while the alternative activation of
M2 macrophages plays a role in healing and repair. In
this study, we observed a marked increase in M2 macro-
phages in AT, lungs and liver of critically ill mice and in
AT of critically ill humans. In AT, M2 accumulation
predominated compared to M1 markers, but in both
liver and lungs of critically ill fed mice, M1 and M2
expression were increased concurrently. In the entire
organism, macrophages are able to rapidly ‘switch’ from
one phenotype to the other depending on the micro-
environment [8]. Thus, a certain degree of overlap of
phenotypes or even an ‘in-between’ phenotype can be
expected [40,41]. From a metabolic point of view, the
M1 to M2 ‘switch’ during critical illness seems highly
beneficial as M2 macrophages are able to efficiently
engulf and b-oxidize FFA, and boost insulin sensitivity
[41,42]. In this case, fasting might add some extra bene-
fit as it is associated with a further M1 to M2 ‘switch’ in
the liver and lungs, thereby possibly protecting against
ectopic lipid accumulation [43,44]. So, quite different
from what is observed in obesity, during CI, M2 macro-
phages predominate. Altogether with the newly-formed
adipocytes, M2 macrophages could prevent or reduce
ectopic lipotoxicity [5,45]. We previously documented
an increased expression of PPARg as a possible trigger
for the M2-phenotyping switch, and not the classically
expected cytokines Il-4 or Il-13 [6]. In this study, we
confirmed an increase in PPARg, the master regulator of
both adipogenesis and M1 to M2 switching [46-48].
Possible activators for PPARg are circulating fatty acids
and locally produced prostaglandins [48].
To assess the clinical relevance of the findings in the
septic mouse model of CI, we studied human subcuta-
neous AT biopsies harvested from adult ICU patients,
who participated in a RCT in which ‘early initiation of par-
enteral nutrition’ was compared with ‘tolerating nutrient
restriction’ during the first week in ICU [12]. In these
biopsies, taken in vivo after one week of illness in the ICU,
we observed comparable alterations as in the mice. In
critically ill humans, we could indeed demonstrate
increased adipogenic markers and M2 macrophage accu-
mulation, irrespective of nutrition.
The following limitations of the study should be high-
lighted: First, a sham group with surgical instrumenta-
tion required for the CLP model was not added. This
was done as the key question was the impact of critical
illness versus health and the role of nutrition versus
nutrient restriction during critical illness. The surgical
instrumentation and the treatment aspects of the model
were considered to be part of the critically ill condition
and its treatment. Second, we a priori postulated a dif-
ference between CLP-fed and healthy-fed mice, with no
difference between CLP-fed and CLP-restricted mice.
For the second negative hypothesis, the study may not
have been specifically powered.
Conclusions
Adipogenesis and M2 macrophage accumulation in AT
appears to be a hallmark of critical illness, independent
of nutritional intake. Accumulation of M2 macrophages
is present not only in AT, but also in the liver and
lungs suggesting an important global role during illness.
Further investigation of the metabolic meaning and
underlying triggers of these alterations may shed light
on the function of adipose tissue during critical illness
and its potential role in the “obesity paradox”.
Key messages
• Adipogenesis and accumulation of tissue M2-
macrophages are hallmarks of prolonged critical ill-
ness, irrespective of nutritional management.
• M2-macrophages accumulate not only in AT, but
also in the liver and lungs.
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